Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
NCT06361888Phase 3Recruiting
- Sponsor
- HUTCHMED
- Start
- May 2024
- Primary completion
- May 2028
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of surufatinib in pancreatic cancer (PC) (3 arms), sponsored by HUTCHMED. Primary endpoint: Overall Survival at 20 months. Started May 2024; status: recruiting.
02
Drugs
surufatinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06361888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361888.